RESEARCH ARTICLE

Systematic Review of Available Guidelines on Fertility Preservation of Young Patients with Breast Cancer

Mahnaz Haddadi¹, Samad Muhammadnejad², Fariba Sadeghi-Fazel³, Zahra Zandieh⁴, Gohar Rahimi⁵, Sanambar Sadighi⁶, Parya Akbari⁷, Mohammad-Ali Mohagheghi⁸, Alireza Mosavi-Jarrahi⁹, Saeid Amanpour¹,⁹* 

Abstract

**Background:** Since the survival rate of breast cancer patients has improved, harmful effects of new treatment modalities on fertility of the young breast cancer patients has become a focus of attention. This study aimed to systematically review and critically appraise all available guidelines for fertility preservation in young breast cancer patients. **Materials and Methods:** Major citation databases were searched for treatment guidelines. Experts from relevant disciplines appraised the available guidelines. The AGREE II Instrument that includes 23 criteria in seven domains (scope and purpose of the guidelines, stakeholder involvement, rigor of development, clarity, applicability, editorial independence, and overall quality) was used to appraise and score the guidelines. **Results:** The search strategy retrieved 2,606 citations; 72 were considered for full-text screening and seven guidelines were included in the study. There was variability in the scores assigned to different domains among the guidelines. ASCO (2013), with an overall score of 68.0%, had the highest score, and St Gallen, with an overall score of 24.7%, had the lowest scores among the guidelines. **Conclusions:** With the promising survival rate among breast cancer patients, more attention should be given to include specific fertility preservation recommendations for young breast cancer patients.

Keywords: Fertility preservation - breast cancer - young women - practice guidelines

*Asian Pac J Cancer Prev, 16 (3), 1057-1062

Introduction

Breast cancer (BC) is the most common malignancy diagnosed in women (Jemal et al., 2011; Bray et al., 2013). It is also the most frequent cancer in young women of reproductive age and comprises approximately 40% of all female cancers in this age group (Jemal et al., 2009). Nearly 2% of BC is diagnosed in young women between 20 and 34 years of age, and 11% between 35 and 44 years of age (Rodriguez-Wallberg and Oktay, 2010). The incidence of breast cancer in young women of reproductive age has been increasing in recent decades (Leclere et al., 2013; Keramatinia et al., 2014). Early diagnosis, adjuvant therapy, and higher cure rates have resulted in longer survival and lower mortality. It is estimated that a 50% increase in the number of patients diagnosed with cancer will occur by 2030. Currently, the five-year survival rate for BC is >90% in developed countries. BC survivors are a major part of cancer survivors in many countries.

Young women with breast cancer are faced with many undesired consequences of cancer therapies, such as long duration of treatment, psychosocial problems, infertility, sexual dysfunction, and even occurrence of other cancers. For these reasons, quality of life remains an important consideration for patients surviving BC, particularly those <40 years of age, and interdisciplinary collaboration has become an essential part of survivor management. Among various side effects of BC, the issues of fertility have been recognized with great importance for young women diagnosed with breast cancer (Sonmezer and Oktay, 2004; Ewertz and Jensen, 2010; Rodriguez-Wallberg and Oktay, 2010; Christinat and Pagani, 2012; Husseinzadeh and Husseinzadeh, 2013; Lange et al., 2013). After the publication of first guidelines on fertility preservation (FP) for cancer patients by American Society of Clinical Oncology (ASCO) in 2006 (Lee et al., 2006), and National Institute for Health and Clinical Excellence (NICE) in 2004 (National Collaborating Center for Women’s
and Children’s Health (UK), 2004), oncologists are recommended to discuss the influences of cancer therapies on fertility with their young patients as early as possible and consider fertility preservation as a part of care. Both of these guidelines were updated recently (Fields et al., 2013; Loren et al., 2013). As a result of considerable improvement in assisted reproductive technology (ART), nowadays there are several options to restore fertility in young women including cryopreservation of oocyte, embryo and ovarian tissue, and in vitro maturation of oocyte before starting cancer treatment. Except embryo freezing, most of these techniques were investigational during the release of the first ASCO and NICE guidelines. Cryopreservation of ovarian tissue seems to be a promising method of preserving fertility in the young breast cancer patients (YBCP). This method is also so important for the patient’s physiology that can avoid menopausal symptoms. Ovarian freezing as the emerging discipline of assisted reproductive technologies is progressively attracting interest to preserve fertility for young cancer patients. Fertility preservation options have also been used for other diseases such as lupus, glomerulonephritis, myelodysplasia, and premature ovarian failure as well as in women who wish to preserve their ovarian function for future reproductive potential and delayed childbearing age (Posada et al., 2001; Imhof et al., 2004; Demeestere et al., 2007; Maltaris et al., 2007; Isachenko et al., 2007; Ajala et al., 2010; Rahimi et al., 2010; Dolmans et al., 2010; Michæl et al., 2012; Husseinzadeh, 2013). Despite rapid progress in cryopreservation technology and existing improvement in assisted reproductive technology (ART), fertility preservation for young breast cancer patients is in its early stage with many challenges.

(Posada et al., 2001; Imhof et al., 2004; National Collaborating Center for Women’s and Children’s Health (UK), 2004; Sonnezer and Oktay, 2004; Lee et al., 2006; Demeestere et al., 2007; Isachenko et al., 2007; Maltaris et al., 2007; Ajala et al., 2010; Dolmans et al., 2010; Ewertz and Jensen, 2010; Rahimi et al., 2010; Christinat and Pagani, 2012; Klemp and Kim, 2012; King et al., 2012; Michæl et al., 2012; Klemp and Kim, 2012; King et al., 2012; Fields et al., 2013; Husseinzadeh, 2013; Husseinzadeh and Husseinzadeh, 2013; Lange et al., 2013; Lecleire et al., 2013; Loren et al., 2013; Ronn and Holzer, 2013). The present study aimed to systematically review available guidelines on preservation of fertility in breast cancer patients.

Materials and Methods

Systematic literature search

A systematic literature search for existing guidelines of FP in patients with BC was performed using MEDLINE and Google Scholar databases. The search strategy comprised three main components: guidelines in any terms, breast cancer in appropriate terms, and fertility preservation in any possible terms (Appendix 1). In addition, eight Guideline Websites were searched including National Guideline Clearing House (http://www.guideline.gov/), National Comprehensive Cancer Network (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp), The Scottish Intercollegiate Guidelines Network (http://www.sign.ac.uk/), The Canadian Medical Association InfoBase for Clinical Practice Guidelines (http://www.cma.ca/cpgs/), Guidelines International Networks (http://www.g-i-n.net/), American College of Physicians Clinical Practice Guidelines (http://www.acponline.org/clinical_information/guidelines/guidelines/), NICE (http://www.nice.org.uk/), and Fertile Hope (http://www.fertilehope.org). Searches were limited to papers published in English language from December 2003 to December 2013. Guidelines to fertility preservation in patients with breast cancer were included using consensus or evidence-based strategies. The latest version was included if the guidelines had been updated.

Quality and content evaluation

The guideline appraisal group comprised four experts from disciplines of medical oncology, epidemiology, cancer surgery, and assisted-reproductive technology. The quality of guidelines was assessed by AGREE II Instrument (AGREE Collaboration, 2003), in which 23 criteria in seven domains were evaluated. These include the scope and purpose of the guidelines, stakeholder involvement, and rigor of development, clarity, applicability, editorial independence, and overall quality. Each appraiser scored the guidelines independently, and results were gathered and analyzed by other investigators who did not participate in the assessment. The appraisers’ scores were expressed as standardized domain scores on a percentage scale (0%-100%).

Results

The search strategy retrieved 2606 citations; 72 were considered for full-text screening, and seven guidelines (Goldhirsch et al., 2009; Von Wolff et al., 2011; Cardoso et al., 2012; Coccia et al., 2012; ISFP Practice Committee et al., 2012; Klemp and Kim, 2012; Loren et al., 2013) were included in the study (Figure 1).

The guidelines included were from the American Society of Clinical Oncology (ASCO 2013), European Society of Breast Cancer Specialists (EUSOMA 2012), International Society for Fertility Preservation (ISFP, May, 22 and 31 2012), National Comprehensive Cancer Network (NCCN 2012), FertiPROTEKT (2011), and St Gallen International Expert Consensus (2009). The ASCO

Systematic Review of Available Guidelines on Fertility Preservation of Young Patients with Breast Cancer

Table 1. AGREE II Domain Scores for Fertility Preservation Guidelines in Patients with Breast Cancer

<table>
<thead>
<tr>
<th>Organization [Year]</th>
<th>Scope and purpose %</th>
<th>Stakeholder involvement %</th>
<th>Rigor of development %</th>
<th>Clarity of presentation %</th>
<th>Applicability %</th>
<th>Editorial independence %</th>
<th>Overall score %</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASCO14[2013]</td>
<td>69.4</td>
<td>91.7</td>
<td>62.5</td>
<td>50</td>
<td>71.9</td>
<td>62.5</td>
<td>68</td>
</tr>
<tr>
<td>EUSOMA30[2012]</td>
<td>45.8</td>
<td>63.8</td>
<td>44.8</td>
<td>62.5</td>
<td>17.7</td>
<td>37.5</td>
<td>45.4</td>
</tr>
<tr>
<td>ISFP26[2012, specific]</td>
<td>79.3</td>
<td>30.6</td>
<td>13</td>
<td>73.6</td>
<td>42.7</td>
<td>50</td>
<td>48.2</td>
</tr>
<tr>
<td>ISFP31[2012, general]</td>
<td>45.8</td>
<td>48.6</td>
<td>6.3</td>
<td>79.2</td>
<td>15.6</td>
<td>50</td>
<td>42</td>
</tr>
<tr>
<td>NCCN32[2012]</td>
<td>47.2</td>
<td>44.4</td>
<td>25</td>
<td>65.3</td>
<td>26</td>
<td>50</td>
<td>45.1</td>
</tr>
<tr>
<td>FertiPROTEKT33[2011]</td>
<td>55.6</td>
<td>61.1</td>
<td>40.6</td>
<td>91.6</td>
<td>44.8</td>
<td>50</td>
<td>57.3</td>
</tr>
<tr>
<td>St Gallen34[2009]</td>
<td>25</td>
<td>43.1</td>
<td>18.8</td>
<td>30.1</td>
<td>18.8</td>
<td>12.5</td>
<td>24.7</td>
</tr>
<tr>
<td>Mean score</td>
<td>52.6</td>
<td>54.8</td>
<td>30.1</td>
<td>64.6</td>
<td>33.9</td>
<td>44.6</td>
<td>47.2</td>
</tr>
</tbody>
</table>

Notes: ASCO=American Society of Clinical Oncology; EUSOMA=European Society of Breast Cancer Specialists; ISFP=International Society for Fertility Preservation; NCCN=National Comprehensive Cancer Network

Table 2. Fertility Preservation Measures Recommended by Guidelines

<table>
<thead>
<tr>
<th>Organization [Year]</th>
<th>Embryo freezing</th>
<th>Egg freezing</th>
<th>Ovarian tissue freezing</th>
<th>Ovarian suppression</th>
<th>Donor eggs</th>
<th>Surrogacy</th>
<th>Adoption</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASCO14[2013]</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
</tr>
<tr>
<td>EUSOMA30[2012]</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
</tr>
<tr>
<td>ISFP26[2012, specific]</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
</tr>
<tr>
<td>ISFP31[2012, general]</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
</tr>
<tr>
<td>NCCN32[2012]</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
</tr>
<tr>
<td>FertiPROTEKT33[2011]</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
</tr>
<tr>
<td>St Gallen34[2009]</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
</tr>
</tbody>
</table>

Only one guideline (ISFP) was exclusively devoted to fertility preservation for young patients with breast cancer, whereas the others recommend fertility preservation for other cancers. Seven fertility preservation procedures recommended for patients were identified across the guidelines (Table 2). Embryo freezing, mature oocyte cryopreservation and ovarian tissue freezing were recommended by all the guidelines. Ovarian suppression using GnRH agonists before chemotherapy were advised by six guidelines (Table 2). Donor eggs, surrogacy, and adoption were proposed only by ASCO.

Discussion

Our study systematically reviewed fertility preservation using major guidelines. The importance of fertility preservation in young breast cancer patients was assessed in the major practicing and currently used guidelines. All the evaluated guidelines had recommendations on fertility preservation for cancer patients undergoing chemotherapy or other treatment modalities with a high risk of infertility.

It is obvious that fertility preservation is an important issue for reproductive-age breast cancer patients. ASCO, NICE, American Society for Reproductive Medicine, and other important organizations recommend that oncology centers should offer fertility counseling to their patients (Goldhirsch, et al., 2009; Pentheroudakis, et al., 2010; Von Wolff, et al., 2011; Klemp and Kim, 2012; Cardoso, et al., 2012; ISFP Practice Committee1, et al., 2012; Fields, et al., 2013; Loren, et al., 2013). Young women represent a relatively small proportion of breast cancer patients and their options for fertility preservation have been limited by many factors such as safety, efficacy issues, and inadequate time before starting cancer therapies. These women experience strong psychosocial distress and also face long-term impairments in their quality of life and fertility. Additionally, the problems of young patients affect some of their relatives, and more people come to bear the breast cancer burden (Sonnezzeer and Oktay, 2004; Cruz et al., 2010; ISFP Practice Committee1 et al., 2012). Studies has reported gaps in young cancer patients receiving fertility counseling even in the developed
countries for a simple reason that a young age at diagnosis reserve enough in future reproductive time (Ronn and Holzer, 2013; Reinecke, 2013). It is estimated that even at the best and most favorable scenario, undergoing anti-hormonal treatment alone can delay pregnancy for at least 5 years. Chemotherapy may cause severe follicle depletion, resulting in a loss of ≥10 years in reproductive function. Conversely, progressive neoadjuvant therapy before surgery is completed in some of these patients with clinically positive nodes or larger tumor size (>2 cm). Neoadjuvant therapy impairs fertility as well as limits the fertility preservation options. Most cases of invasive BC occur between 30 and 40 years of age, shedding light on the critical role of age in diagnoses for desirable fertility preservation. In healthy females, after the age of 37–38 years, >90% of oocytes present at birth have already undergone atresia. Therefore, there are differences between the characterization of a young woman in oncology and gynecology (Kim et al., 2011; Lobo, 2005; Peccatori et al., 2012). The age-related fertility preservation options are not completely clear in current guidelines for oncologists, and may be very important because the value of early fertility preservation counseling for young cancer patient fully depends on it. Rapid counseling may allow YBCP sufficient time for one or two rounds of egg collection without delaying the start of their cancer treatment (Kim et al., 2011). Some investigators have reported that the benefit of GnRH agonist therapy to protection of ovaries is unproven and it should not be offered as individual method of fertility preservation in young breast cancer patient (Sonnezzer and Oktay, 2006; Bedoschi et al., 2013). Recent studies suggest that GnRH with chemotherapy in premenopausal women is associated with higher rates of resumption of menses, although it is not associated with improvement in pregnancy rates. Usage of less gonadotoxic regimens for adjuvant or neoadjuvant chemotherapy is a good choice and may be considered in YBCP with favorable tumors characteristic (Lobo, 2005; Kim et al., 2011). When cryopreservation of embryos or oocytes is not possible, ovarian tissue cryopreservation can be considered without a delay in cancer treatment (Oktay et al., 2003; 2005; Dolmans et al., 2010; Rahimi et al., 2010; Kim et al., 2011; ISFP Practice Committee et al., 2012; Husseinizadeh, 2013). Although many scientific or technical aspects of fertility preservation options are presented in current recommendations and guidelines, this matter raises several important ethical and legal issues that should be adequately addressed to young patients or parents before such techniques are used. Any decision must be in the patient’s preference and best interest. A very informed consent to accept any fertility preservation options is both a legal and an ethical need that must take consideration in practice (Ethics Committee of the American Society for Reproductive Medicine, 2005; Wallace et al., 2005; Jeruss and Woodruff, 2009; Klock et al., 2010). Fertility preservation in cancer patients is an interdisciplinary approach. It needs the simultaneous functions of many components, which is a challenge. Many studies have shown that the most important weak points are poor access and referral to fertility services, low level of knowledge, and lack of available education for patients and health care providers (Forman et al., 2010; Klemp and Kim, 2012; King et al., 2012; Ronn and Holzer, 2013; Peate et al., 2013; Lange et al., 2013). Fertility preservation in breast cancer patients is even more complicated in underdeveloped countries with unsatisfactory health care infrastructure. Breast cancer survivors are one of the largest portion of cancer survivors (Dizon, 2009). Our results and many other reports demonstrate that comprehensive, specific, and practical guidelines for young breast cancer patients’ fertility preservation are rare (Ethics Committee of the American Society for Reproductive Medicine, 2005; Von Wolff et al., 2011). The lack of a suitable guideline that covers all aspects of fertility preservation in young patients with breast cancer is evident. An appropriate guideline for YBCP needs to offer fertility preservation options, considering costs, practicality, social values, and ethical consequences. Such a guideline should consider establishment of a multidisciplinary approach, providing effective engagement between oncologists, fertility specialists, and patients. Fertility preservation should be routinely started as early as possible after the diagnosis of breast cancer. Such a system also helps to decrease the pressure of decision making for both the patient and the oncologist.

In conclusion, in this study, we retrieved seven guidelines of fertility preservation for breast cancer patients. Critical appraisal of the present guidelines indicates that these guidelines do not appropriately address all aspects of a comprehensive guideline development. Not all available guidelines address specific recommendations for fertility preservation in young breast cancer patients. With the promising survival rate among breast cancer patients, more attention should be given to specific fertility preservation recommendations in young breast cancer patients.

Acknowledgements

The authors express their gratitude to Dr. Kazem Zendehdel and Dr. Bahman Mazheri who supported the development of this work. This work was supported with a grant from the Cancer Models Research Center, Tehran University of Medical Sciences, Tehran, Iran.

References


